India’s patent policy: Big Pharma’s grouse?
In a congressional hearing last week, Roy Waldron, Chief Intellectual Property (IP) counsel of American Pharma giant, Pfizer raised concerns over India’s “protectionist” IP regime. The Capitol Hill testimony can be accessed here. Waldron alleged that since the advent of the product patent regime in 2005, India has continually defied trade rules and supported the domestic generic industry at the expense of innovators. On the other hand Indian generic industry has increased its US sales dramatically. To quote “Three […]
India’s patent policy: Big Pharma’s grouse? Read More »